Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
The cheapest Etoposide Phosphate (BMY-40481) (CAS No.: 117091-64-2) is for research use only. Significant discount for bulk order of Etoposide Phosphate (BMY-40481). Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
A potent anti-cancer chemotherapy agent and a selective topoisomerase II inhibitor to prevent re-ligation of DNA strands. Etoposide phosphate is the phosphate ester prodrug of etoposide and is considered as active equivalent to Etoposide. Etoposide phosphate induces cell cycle arrest, apoptosis, and autophagy.
CAS No.: 117091-64-2
IUPAC/Chemical Name: [4-[(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenyl] dihydrogen phosphate
Molecular Formula: C29H33O16P
Molecular Weight: 668.54
Purity: 99% (HPLC)
QC: LC/MS, 1HNMR
Solubility: Soluble in DMSO and water
Storage: Store at 0 °C (short term), -20 °C (long term), Desiccated
Note: Please contact us for COA, Spectra, and SDS information.
Background Information:
Etoposide phosphate (BMY-40481) (CAS No.: 117091-64-2), a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Target: Topoisomerase II
IC50: 0.945 μM (HCT116 FBXW+/+), 0.375 μM (HCT116 FBXW-/-), and 1.437 μM (HCT116 p53-/-)
In Vitro: Etoposide phosphate is a water-soluble derivative and probable prodrug of etoposide characterized by the presence of a phosphate group in position 4′ of the E ring of the etoposide molecule.[1]
Etoposide phosphate (0-1 μM; 72 hours) inhibits HCT116 FBXW+/+, FBXW-/- and p53-/- as a dose-dependent manner, exhibits IC50 values of 0.945 μM; 0.375 μM; and 1.437 μM, respectively.[2]
Etoposide phosphate (25 μM; 6 hours) delays p53 recover in FBXW7-deficient cells. In addition, FBXW7 expression is disappeared in FBXW7-/- cells.[2]
In Vivo: Etoposide phosphate (intravenous injection; 50, 100, or 150 mg/kg; single dose) has clinical symptomology of progressive ataxia, impaired righting reflex, and splaying and paresis of fore- and hindlimbs at day 8 in female CD-1 mice.[3]
What is the solubility of Etoposide phosphate (BMY-40481) in vitro?
125 mg/mL in H2O (Need ultrasonic)
Reference:
[1]. Witterland, A. H. et al. “Etoposide Phosphate, the Water Soluble Prodrug of Etoposide”, Pharm. World Sci. 1996, 18, 163-170.
[2]. Cui, D. et al. “FBXW7 Confers Radiation Survival by Targeting p53 for Degradation”, Cell Rep. 2020, 30, 497-509.
[3]. Bregman, C. L. et al. “Etoposide- and BMY-40481-Induced Sensory Neuropathy in Mice”, Toxicol. Pathol. 1994, 22, 528-535.
[4]. Millward, M. J. et al. “Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481)”, Eur. J. Cancer 1995, 31, 2409-2411.
[5]. Doyle, T. W. et al. “Second generation analogs of etoposide and mitomycin C”, Cancer Treat. Rev. 1990, 17, 127-131.
[6]. Saulnier, M. G. et al. “E-ring desoxy analogs of etoposide”, J. Med. Chem. 1989, 32, 1418-1420.
[7]. Saulnier, M. G. et al. “Synthesis of etoposide phosphate, BMY-40481: A water-soluble clinically active prodrug of etoposide”, Bioorg. Med. Chem. Lett. 1994, 4, 2567-2572.
Copyright © 2009-2022 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.